乳腺癌传统治疗手段如何焕发新活力？

Core Viewpoint - The article emphasizes the importance of personalized treatment in breast cancer management, highlighting advancements in molecular profiling and the need for continuous monitoring to reduce recurrence risks [1][2][3][4][5] Group 1: Cancer Prevention and Awareness - The 31st National Cancer Prevention Week is scheduled from April 15 to 21, 2025, aiming to enhance cancer prevention awareness and encourage individuals to take responsibility for their health [1] - The "People's Good Doctor · Jinshan Camellia Plan" series aims to promote cancer prevention knowledge through expert discussions [1] Group 2: Molecular Profiling in Breast Cancer Treatment - Breast cancer treatment has transitioned to a "classification-based" approach, where molecular profiling acts as a "genetic ID" that determines treatment pathways [2] - Different molecular subtypes of breast cancer (e.g., hormone receptor-positive, HER2-positive, triple-negative) require distinct treatment strategies, with hormone receptor-positive patients making up approximately 70% of cases [2] Group 3: Recurrence Risk Management - Post-surgery, patients must undergo lifelong follow-up, with specific monitoring schedules to detect recurrence early [3] - Recurrence risk is influenced by tumor biology, pathological staging, and adherence to treatment protocols, with non-compliance potentially increasing recurrence rates by 2-3 times [3] Group 4: Endocrine Therapy - Hormone receptor-positive patients face a prolonged endocrine therapy period of 5-10 years, significantly reducing recurrence risk [4] - Clinical data indicates that 5-year endocrine therapy can lower recurrence risk by 50%, with high-risk patients benefiting from extended treatment [4] Group 5: Future of Precision Medicine - Advances in molecular testing are leading to the identification of numerous breast cancer subtypes, paving the way for truly personalized treatment plans based on individual molecular characteristics [5] - The article suggests that breast cancer may become one of the first solid tumors to achieve "precision cure" through emerging technologies like gene editing and mRNA vaccines [5] - The 5-year survival rate for breast cancer patients in China has improved to 83%, reflecting a shift from merely curing the disease to enhancing the quality of life [5]